2017 Annual Meeting

ASBrS 2017 Vendor Symposia

 

Vendor-supported symposia, which have been made possible through marketing support, are offered each year during the annual meeting. The Society would like to give members and attendees who might not have been able to attend the symposia in Las Vegas access to the program content. Below are links that will take interested attendees to vendor website where the handout materials/information and/or video/recording of the specific symposium will be available.    

NOTE: Vendor satellite symposia are supported by specific companies and are supported through a marketing grant. They are not part of the official program of the ASBrS and are free to all registered attendees.

Disclaimer:  By clicking the posted link, please understand you are leaving the ASBrS website and going to a website that is not operated by the Society.

THURSDAY EVENING SYMPOSIUM

Thursday, April 27

Genomic Health, Inc.

Genomic Assays and Patient Outcomes: Real-world Applications

Overall Program Objective: 
To offer perspectives on the analysis of outcomes data and their application in the choice of genomic assays for patients with early-stage breast cancer to enable informed treatment planning.

Description of Program: 
This program featured a panel discussion with 3-4 physician speakers presenting a range of patient cases and the implications of using genomic classifiers in the management of early-stage breast cancer. The program also included a review and analysis of several key studies with outcomes data, eg TAILORx Trial, SEER and Clalit Breast Cancer Registry (Israel), and restaging using the 8th Edition of the AJCC Cancer Staging Manual. 

Click here for more information on the AJCC section of the program: restaging using the 8th Edition of the AJCC Cancer Staging Manual. 

NOTE: This satellite symposium is supported by Genomic Health, Inc., through a marketing grant. It is not part of the official program of the ASBrS. This activity is free to all registered attendees.

Disclaimer:  By clicking the posted link, please understand you are leaving the ASBrS website and going to a website that is not operated by the Society.


Friday evening Symposia

Friday, April 28, 2017

Genentech, Inc.
Invuity, Inc.
Myriad Genetics, Inc.


Genentech, Inc.

Case-Based Preoperative Considerations in HER2+ Breast Cancer: A Multidisciplinary Approach
PROGRAM OVERVIEW: 
This program discussed the use of PERJETA for the neoadjuvant treatment of HER2-positive early breast cancer by focusing on: case studies discussing appropriate patient selection for preoperative treatment, 2013 ASCO/CAP guidelines for HER2 testing, and clinical trial data on pathological complete response (pCR).

For more information about the program, please visit: http://www.perjeta.com/neoadjuvant-her2-positive-breast-cancer-treatment.

NOTE: This satellite symposium is supported by Genentech, Inc., through a marketing grant. It is not part of the official program of the ASBrS.

Disclaimer:  By clicking the posted link, please understand you are leaving the ASBrS website and going to a website that is not operated by the Society. .

back to Friday Evening Symposia


Invuity, Inc.

Advanced Techniques, Considerations & Technologies in Hidden Scar™ Breast Cancer Surgery

Description of Program: 
This symposium discussed the advanced techniques, considerations, and enabling technologies in Hidden Scar Breast Conserving Surgery and Hidden Scar Nipple Sparing Mastectomy that prioritize both the oncologic and psychosocial outcomes essential for breast cancer survivorship.  The faculty discussed how intracavity illumination enhanced energy and near infrared imaging technologies impact surgical experience and clinical outcomes. 

Please click the following link to view the presentation:  https://youtu.be/IqXcFkutaiM.

NOTE: This satellite symposium is supported by Invuity, Inc., through a marketing grant. It is not part of the official program of the ASBrS.

Disclaimer:  By clicking the posted link, please understand you are leaving the ASBrS website and going to a website that is not operated by the Society.

back to Friday Evening Symposia


Myriad Genetics, Inc.

The Future of Breast Cancer Recurrence Testing – A Scientific Introduction to EndoPredict

Gain an understanding of the clinical benefits of Myriad’s EndoPredict breast cancer recurrence test including the scientific development and clinical validation of EndoPredict, as well as clinical application of the EndoPredict test result. EndoPredict predicts early and late recurrence risk for patients with ER+, HER2- early stage breast cancer and up to 3 positive lymph nodes. This program explored the data supporting the use of EndoPredict to assess the risk of distant metastases in years 0 to 10 post diagnosis when treated with 5 years of endocrine therapy.

Click here for more information about the program, The Future of Breast Cancer Recurrence Testing – A Scientific Introduction to EndoPredict.

NOTE: This satellite symposium is supported by Myriad Genetics Laboratories, Inc., through a marketing grant. It is not part of the official program of the ASBrS. This activity is free to all registered attendees.

Disclaimer:  By clicking the posted link, please understand you are leaving the ASBrS website and going to a website that is not operated by the Society.

back to Friday Evening Symposia


 

Saturday Breakfast Symposia

Programs:

top of page


Albert Einstein College of Medicine

Virtual Cadaver Hand-On Workshop: Identifying Breast and Abdominal Planes for Surgical Infiltration to Manage Post-Surgical Pain

Overall Program Objectives:

  • Describe the opioid epidemic and associated adverse events with opioids.
  • Review the multimodal options utilized pre-op, inter-op and post-op in breast reconstruction surgery.
  • Identify the surgical anatomy targeting PECS I, II, III, serratus, classic tap, subcostal and rectus sheath blocks.
  • Adapt techniques via hands-on practice on live models and phantom stations.

For more information, please contact Joyce Davis at joyce.davis@pacira.com. 

Note: This satellite symposium was supported by Pacira Pharmaceuticals through an educational grant provided to Albert Einstein College of Medicine. CME credits for this program were provided by Albert Einstein College of Medicine. It was not part of the official program of the ASBrS*. (*An independent grant from Albert Einstein College of Medicine was provided to the ASBrS in order to offer this satellite symposium during the 18th Annual Meeting.)

Disclaimer:  By clicking the posted link, please understand you are leaving the ASBrS website and going to a website that is not operated by the Society.

back to Saturday Breakfast Symposia


BioTheranostics

The Role of Genomics in Patient Selection for Extended Endocrine Therapy

Description:
Recent data on extended adjuvant endocrine therapy has emphasized the need for an individualized approach to identify candidates for prolonged treatment.  This presentation puts the recent data in the context of previous extended endocrine therapy trials and provides insight on how breast surgeons may apply the data in clinical practice by introducing a genomic assay that can help physicians with patient selection.

Please click the following link to view presentation: The Role of Genomics in Patient Selection for Extended Endocrine Therapy.

NOTE: This satellite symposium is supported by Biotheranostics, through a marketing grant. It is not part of the official program of the ASBrS.

Disclaimer:  By clicking the posted link, please understand you are leaving the ASBrS website and going to a website that is not operated by the Society.

back to Saturday Breakfast Symposia


Cianna Medical

Moving Beyond Wires:  A Non-Radioactive Solution to Breast Tumor Localization

Program Objectives: 
To learn more about the SAVI SCOUT, an FDA-Cleared surgical guidance system to provide real-time guidance during lumpectomies

Please click the following link to view presentation: https://vimeo.com/229875640

NOTE: This satellite symposium is supported by Cianna Medical, Inc., through a marketing grant. It is not part of the official program of the ASBrS.

Disclaimer:  By clicking the posted link, please understand you are leaving the ASBrS website and going to a website that is not operated by the Society.

back to Saturday Breakfast Symposia


Dune Medical Devices and Carl Zeiss Meditec

Negative Margins in TARGiT IORT: Methods and techniques for achieving the most favorable result

Description: 
This program discussed techniques for achieving negative margins when employing TARGiT Intraoperative Radiation Therapy for breast conserving surgery patients.  The program combined presentation and panel discussion on two synergistic technologies: MarginProbe to overcome the challenges with margins in BCS; and TARGiT Intrabeam on proper patient selection, management, and follow-up of IORT patients.

For more information about the program, please visit http://marginprobe.com/american-society-of-breast-surgeons-asbrs-2017/.
 
NOTE: This satellite symposium is supported by Dune Medical Devices, Inc. and Carl Zeiss Meditec through a marketing grant. It is not part of the official program of the ASBrS.

Disclaimer:  By clicking the posted link, please understand you are leaving the ASBrS website and going to a website that is not operated by the Society.

back to Saturday Breakfast Symposia


Focal Therapeutics, Inc.

Improving Your Outcomes with Oncoplastic Surgery: Techniques in "Reconstructive Lumpectomy"

Brief Description of Program:
Topics include principles and practice of oncoplastic breast conserving surgery with specific attention focused on "reconstructive lumpectomy".  Integration of the BioZorb implant was covered including tips on patient selection, surgical techniques, and other "pearls" on how to optimize patient outcomes.  Impact on radiation therapy and coding for oncoplastic surgery were also addressed.

For more information about the program, please contact Brian Driscoll at bdriscoll@focalrx.com or visit http://www.focalrx.com/.

NOTE: This satellite symposium is supported by Focal Therapeutics through a marketing grant. It is not part of the official program of the ASBrS.

Disclaimer:  By clicking the posted link, please understand you are leaving the ASBrS website and going to a website that is not operated by the Society.

back to Saturday Breakfast Symposia


ImpediMed, Inc.

The Future of Survivorship

Description of Program: 
The battle of lymphedema begins with L-Dex. This event discussed the changes in the field of oncology, what is to come in the world of survivorship and how to continuously strive to find ways to improve the patient’s quality of life.

To view the program, please visit:  https://wp.me/P76aTU-1Yi.

NOTE: This satellite symposium is supported by ImpediMed, Inc., through a marketing grant. It is not part of the official program of the ASBrS.

Disclaimer:  By clicking the posted link, please understand you are leaving the ASBrS website and going to a website that is not operated by the Society.

back to Saturday Breakfast Symposia